Effects of biphenyl sulfonylamino methyl bisphosphonic acids on Porphyromonas gingivalis and cytokine secretion by oral epithelial cells

Medicinal Chemistry

Volumn 9, Issue 6, 2013, Pages 855-860

  Zhao, Lei ^a   Marquis, Annie ^b   La, Vu Dang ^b   Agamennone, Mariangela ^c   Loiodice, Fulvio ^d   Tortorella, Paolo ^d   Grenier, Daniel ^b  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Anti inflammatory; Antibacterial; Bisphosphonate; Periodontal disease

Indexed keywords

(4 CHLORO BIPHENYL 4 SULFONYLAMINO)METHYL 1,1 BISPHOSPHONIC ACID; (4 METHOXY PHENYLSULFONYLAMINO)METHYL 1,1 BISPHOSPHONIC ACID; (4 NITRO PHENYLSULFONYLAMINO)METHYL 1,1 BISPHOSPHONIC ACID; (BIPHENYL 4 SULFONYLAMINO) METHYL 1,1 BISPHOSPHONIC ACID; ARYLSULFONAMIDE BISPHOSPHONATE; BIPHENYL SULFONYLAMINO METHYL BISPHOSPHONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; INTERLEUKIN 6; INTERLEUKIN 8; IRON; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ARTICLE; BACTERIAL GROWTH; CYTOKINE RELEASE; EPITHELIUM CELL; ORAL EPITHELIAL CELL; PERIODONTAL DISEASE; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BIPHENYL COMPOUNDS; CELLS, CULTURED; CYTOKINES; DIPHOSPHONATES; HUMANS; MOUTH MUCOSA; PORPHYROMONAS GINGIVALIS; SULFONAMIDES;

EID: 84883414941     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406411309060009     Document Type: Article

References (27)

1. Byrne, S.J.; Dashper, S.G.; Darby, I.B.; Adams, G.G.; Hoffmann, B.; Reynolds, E.C. Progression of chronic periodontitis can be predicted by the levels of Porphyromonas gingivalis and Treponema denticola in subgingival plaque. Oral Microbiol. Immunol., 2009, 4, 469-77.
2. Armitage, G.C. Comparison of the microbiological features of chronic and aggressive periodontitis. Periodontol. 2000, 2010, 53, 70-88.
3. Holt, S.C.; Ebersole, J.L. Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis. Periodontol. 2000, 2005, 38, 72-122.
4. Liu, Y.C.; Lerner, U.H.; Teng, Y.T. Cytokine responses against periodontal infection: protective and destructive roles. Periodontol. 2000, 2010, 52, 163-206.
5. Darveau, R.P. Periodontitis: a polymycrobial disruption of host homeostasis. Nat. Rev. Microbiol., 2010, 8, 481-90.
6. Pizzo, G.; Guiglia, R.; Russo, L.L.; Campisi, G. Dentistry and internal medicine: from the focal infection theory to the periodontal medicine concept. Eur. J. Int. Med., 2010, 21, 496-502.
7. Ebetino, F.H.; Hogan, A.M.; Sun, S.; Tsoumpra, M.K.; Duan, X.; Triffitt, J.T.; Kwaasi, A.A.; Dunford, J.E.; Barnett, B.L.; Oppermann, U.; Lundy, M.W.; Boyde, A.; Kashemirov, B.A.; McKenna, C.E.; Russell, R.G. The relationship between the chemistry and biological activity of the bisphosphonates. Bone, 2011, 49, 20-33.
8. Gumienna-Kontecka, E.; Silvagni, R.; Lipinski, R.; Lecouvey, M.; Cesare Marincola, F.; Crisponi, G.; Nurchi, V.M.; Leroux, Y.; Kozlowski, H. Bisphosphonate chelating agents: complexation of Fe(III) and A1(III) by 1-phenyl-1-hydroxymethylene bisphosphonate and its analogues. Inorg. Chim. Acta, 2002, 339, 111-18.
9. 2+ salt of pamidronate: a role for water in the metal-cation binding properties of bisphosphonates. Acta Crystallogr. C, 2004, 60, 73-5.
10. Drake, M.T.; Cremers, S.C. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Mol. Interv., 2010, 10, 141-52.
11. Tenenbaum, H.C.; Shelemay, A.; Girard, B.; Zohar, R.; Fritz, P.C. Bisphosphonates and periodontics: Potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J. Periodontol., 2002, 73, 813-22.
12. Roelofs, A.J.; Thompson, K.; Ebetino, F.H.; Rogers, M.J.; Coxon, F.P. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr. Pharm. Des., 2010, 16, 2950-60.
13. Boissier, S.; Ferreras, M.; Peyruchaud, O.; Magnetto, S.; Ebetino, F.H.; Colombel, M.; Delmas, P.; Delaisse, J.M.; Clezardin, P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res., 2000, 60, 2949-54.
14. Heikkila, P.; Teronen, O.; Moilanen, M.; Konttinen, Y.T.; Hanemaaijer, R.; Laitinen, M.; Maisi, P.; van der Pluijm, G.; Bartlett, J.D.; Salo, T.; Sorsa, T. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs, 2002, 13, 245-54.
15. Rubino, M.T.; Agamennone, M.; Campestre, C.; Fracchiolla, G.; Laghezza, A.; Loiodice, F.; Nuti, E.; Rossello, A.; Tortorella, P. Synthesis, SAR, and biological evaluation of alphasulfonylphosphonic acids as selective matrix metalloproteinase inhibitors. Chem Med Chem, 2009, 4, 352-62.
16. Folgueras, A.R.; Fueyo, A.; Garcia-Suarez, O.; Cox, J.; Astudillo, A.; Tortorella, P.; Campestre, C.; Gutierrez-Fernandez, A.; Fanjul-Fernandez, M.; Pennington, C.J.; Edwards, D.R.; Overall, C.M.; Lopez-Otin, C. Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J. Biol. Chem., 2008, 283, 9465-74.
17. Biasone, A.; Tortorella P.; Campestre, C.; Agamennone, M.; Preziuso, S.; Chiappini, M.; Nuti, E.; Carelli, P.; Rossello, A.; Mazza, F.; Gallina, C. alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs. Bioorg. Med. Chem., 2007, 15, 791-99.
18. Pochetti, G.; Gavuzzo, E.; Campestre, C.; Agamennone, M.; Tortorella, P.; Consalvi, V.; Gallina, C.; Hiller, O.; Tschesche, H.; Tucker, P.A.; Mazza, F. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J. Med. Chem., 2006, 49, 923-31.
19. Rubino, M.T.; Agamennone, M.; Campestre, C.; Campiglia, P.; Cremasco, V.; Faccio, R.; Laghezza, A.; Loiodice, F.; Maggi, D.; Panza, E.; Rossell, A.; Tortorella, P. Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption. Chem Med Chem, 2011, 6, 1258-68.
20. Herczegh, P.; Buxton, T.B.; McPherson, J.C.; Kovács-Kulyassa, A.; Brewer, P.D.; Sztaricskai. F.; Stroebel, G.G.; Plowman, K.M.; Farcasiu, D.; Hartmann, J.F. Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials. J. Med. Chem., 2002, 45, 2338-41.
21. Crisponi, G.; Nurchi, V.M.; Pivetta, T. Potentiometric and spectrophotometric equilibrium study on Fe(III) and new catecholbisphosphonate conjugates. J. Inorg. Biochem., 2008, 102, 209-15.
22. Denyer, S.P.; Maillard, J.Y. Cellular impermeability and uptake of biocides and antibiotics in Gram-negative bacteria. J. Appl. Microbiol., 2002, 92, 35S-45S.
23. Monkkonen, J.; Pennanen, N.; Lapinjoki, S.; Urtti, A. Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells. Life Sci., 1994, 54, PL229-34.
24. Salkowski, C.A.; Neta, R.; Wynn, T.A.; Strassmann, G.; Van Rooijen, N.; Vogel, S.N. Effect of liposome-mediated macrophage depletion on LPS-induced cytokine gene expression and radioprotection. J. Immunol., 1995, 155, 3168-79.
25. Tamai, R.; Sugiyama, A.; Kiyoura, Y. Alendronate regulates cytokine production induced by lipid A through nuclear factor-B and Smad3 activation in human gingival fibroblasts. J. Periodont. Res., 2011, 46, 13-20.
26. Tipton, D.A.; Seshul, B.A.; Dabbous, M.K. Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. J. Periodont. Res., 2011, 46, 39-47.
27. Santini, D.; Fratto, M.E.; Vincenzi, B.; Cesa, A.L.; Dianzani, C.; Tonini, G. Bisphosphonate effects in cancer and inflammatory diseases: and modulation of cytokine activities. Bio Drugs, 2004, 18, 269-78.